ORGO Relative Valuation
ORGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORGO is overvalued; if below, it's undervalued.
Historical Valuation
Organogenesis Holdings Inc (ORGO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 35.79. The fair price of Organogenesis Holdings Inc (ORGO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.92
Fair
23.43
PE
1Y
3Y
5Y
Trailing
Forward
9.90
EV/EBITDA
Organogenesis Holdings Inc. (ORGO) has a current EV/EBITDA of 9.90. The 5-year average EV/EBITDA is 14.30. The thresholds are as follows: Strongly Undervalued below 0.34, Undervalued between 0.34 and 7.32, Fairly Valued between 21.27 and 7.32, Overvalued between 21.27 and 28.25, and Strongly Overvalued above 28.25. The current Forward EV/EBITDA of 9.90 falls within the Historic Trend Line -Fairly Valued range.
16.53
EV/EBIT
Organogenesis Holdings Inc. (ORGO) has a current EV/EBIT of 16.53. The 5-year average EV/EBIT is 31.56. The thresholds are as follows: Strongly Undervalued below -86.28, Undervalued between -86.28 and -27.36, Fairly Valued between 90.48 and -27.36, Overvalued between 90.48 and 149.41, and Strongly Overvalued above 149.41. The current Forward EV/EBIT of 16.53 falls within the Historic Trend Line -Fairly Valued range.
1.17
PS
Organogenesis Holdings Inc. (ORGO) has a current PS of 1.17. The 5-year average PS is 1.66. The thresholds are as follows: Strongly Undervalued below -1.01, Undervalued between -1.01 and 0.32, Fairly Valued between 3.00 and 0.32, Overvalued between 3.00 and 4.33, and Strongly Overvalued above 4.33. The current Forward PS of 1.17 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Organogenesis Holdings Inc. (ORGO) has a current P/OCF of 0.00. The 5-year average P/OCF is 15.68. The thresholds are as follows: Strongly Undervalued below -24.37, Undervalued between -24.37 and -4.34, Fairly Valued between 35.71 and -4.34, Overvalued between 35.71 and 55.73, and Strongly Overvalued above 55.73. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Organogenesis Holdings Inc. (ORGO) has a current P/FCF of 0.00. The 5-year average P/FCF is -8.80. The thresholds are as follows: Strongly Undervalued below -374.89, Undervalued between -374.89 and -191.84, Fairly Valued between 174.25 and -191.84, Overvalued between 174.25 and 357.30, and Strongly Overvalued above 357.30. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Organogenesis Holdings Inc (ORGO) has a current Price-to-Book (P/B) ratio of 2.45. Compared to its 3-year average P/B ratio of 1.66 , the current P/B ratio is approximately 47.75% higher. Relative to its 5-year average P/B ratio of 3.99, the current P/B ratio is about -38.62% higher. Organogenesis Holdings Inc (ORGO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.65%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.26% , the current FCF yield is about -100.00% lower.
2.45
P/B
Median3y
1.66
Median5y
3.99
-8.16
FCF Yield
Median3y
-1.65
Median5y
-0.26
Competitors Valuation Multiple
The average P/S ratio for ORGO's competitors is , providing a benchmark for relative valuation. Organogenesis Holdings Inc Corp (ORGO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 30.98%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ORGO increased by 53.75% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.71 to 14.30.
The secondary factor is the Revenue Growth, contributed 30.98%to the performance.
Overall, the performance of ORGO in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Organogenesis Holdings Inc (ORGO) currently overvalued or undervalued?
What is Organogenesis Holdings Inc (ORGO) fair value?
How does ORGO's valuation metrics compare to the industry average?
What is the current P/B ratio for Organogenesis Holdings Inc (ORGO) as of Dec 05 2025?
What is the current FCF Yield for Organogenesis Holdings Inc (ORGO) as of Dec 05 2025?
What is the current Forward P/E ratio for Organogenesis Holdings Inc (ORGO) as of Dec 05 2025?